^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

Viral entry inhibitor

6d
New trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Vyrologix (leronlimab)
14d
Pharmacological Intervention to Prevent NOAF After TAVR (clinicaltrials.gov)
P=N/A, N=198, Not yet recruiting, Shanghai East Hospital
New trial
20d
Trial initiation date
|
CD4 (CD4 Molecule)
27d
Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies (clinicaltrials.gov)
P=N/A, N=51, Recruiting, IRCCS Ospedale San Raffaele | Not yet recruiting --> Recruiting
Enrollment open
29d
Papillary Thyroid Carcinoma in a Patient With a Germline Titin (TTN) Mutation. (PubMed, Cureus)
Owing to the large size of the TTN gene, recurrent mutations are frequently observed across cancer datasets, but the clinical and biological significance of these alterations, particularly in the germline setting, remains incompletely understood. This case presents a patient with a germline TTN mutation who was diagnosed with papillary thyroid carcinoma after he developed amiodarone-induced thyrotoxicosis.
Journal
|
TTN (Titin)
1m
Trial completion date • Trial initiation date
|
CD4 (CD4 Molecule)
1m
AMIODETECT: Comparative Efficacy of 100-, 200-, & 400-mg Amiodarone in Patients With Paroxysmal AF Depending on Plasma Concentration (clinicaltrials.gov)
P4, N=80, Enrolling by invitation, Tomsk National Research Medical Center of the Russian Academy of Sciences
New P4 trial
1m
Enrollment closed
|
CD4 (CD4 Molecule)